Suppr超能文献

通络解毒方对口腔癌患者免疫功能和氧化应激的影响

Effects of Tongluo Jiedu prescription on immune function and oxidative stress in patients with oral cancer.

作者信息

Yin Yue, Yao Yuan, Li Yi-Jie, Zhao Li-Li, Zhang Qiang

机构信息

Department of Stomatology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei Province, China.

出版信息

World J Clin Cases. 2024 Jun 16;12(17):3045-3052. doi: 10.12998/wjcc.v12.i17.3045.

Abstract

BACKGROUND

Oral cancer, which is caused by mucous membrane variation, represents a prevalent malignant tumor in the oral and maxillofacial region, posing a significant threat to patients' lives and safety. While surgical intervention stands as a cornerstone treatment for oral cancer patients, it carries the risk of incomplete treatment or high rates of postoperative recurrence. Hence, a multifaceted approach incorporating diverse treatment modalities is essential to enhance patient prognosis.

AIM

To analyze the application effect of Tongluo Jiedu prescription as adjuvant therapy and its influence on patient prognosis in patients with oral cancer.

METHODS

Eighty oral cancer patients in our hospital were selected and divided into the observation group and control group by a random number table. The control group was treated with continuous arterial infusion chemotherapy of cisplatin and 5-fluorouracil. The observation group was additionally given Tongluo Jiadu prescription. The inflammatory stress level, peripheral blood T-cell subsets, and immune function of the two groups were subsequently observed. SPSS 21.0 was used for data analysis.

RESULTS

The observation group demonstrated lower levels of interleukin-6 and C-reactive protein, and a higher level of tumor necrosis factor in comparison to the control group. After treatment, the immune function in the observation group was significantly better than in the control group.

CONCLUSION

Tongluo Jiedu prescription can improve the immune function and oxidative stress level of patients with oral cancer and accelerate the recovery process.

摘要

背景

口腔癌是由黏膜变异引起的,是口腔颌面部常见的恶性肿瘤,对患者的生命和安全构成重大威胁。虽然手术干预是口腔癌患者的基石治疗方法,但存在治疗不彻底或术后复发率高的风险。因此,采用多种治疗方式的多方面方法对于改善患者预后至关重要。

目的

分析通络解毒方作为辅助治疗在口腔癌患者中的应用效果及其对患者预后的影响。

方法

选取我院80例口腔癌患者,采用随机数字表法分为观察组和对照组。对照组采用顺铂和5-氟尿嘧啶持续动脉灌注化疗。观察组在此基础上加用通络解毒方。随后观察两组的炎症应激水平、外周血T细胞亚群和免疫功能。采用SPSS 21.0进行数据分析。

结果

与对照组相比,观察组白细胞介素-6和C反应蛋白水平较低,肿瘤坏死因子水平较高。治疗后,观察组的免疫功能明显优于对照组。

结论

通络解毒方可以改善口腔癌患者的免疫功能和氧化应激水平,加速恢复进程。

相似文献

1
Effects of Tongluo Jiedu prescription on immune function and oxidative stress in patients with oral cancer.
World J Clin Cases. 2024 Jun 16;12(17):3045-3052. doi: 10.12998/wjcc.v12.i17.3045.
4
[Effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Jul;33(7):815-820. doi: 10.3760/cma.j.cn121430-20201228-00776.
10
[Huotan Jiedu Tongluo decoction alleviates early atherosclerosis of rabbits by inhibiting eNOS uncoupling pathway].
Zhongguo Zhong Yao Za Zhi. 2018 Nov;43(21):4305-4310. doi: 10.19540/j.cnki.cjcmm.20180820.004.

引用本文的文献

1
Tongluo Jiedu as an adjuvant therapy for oral cancer.
World J Clin Cases. 2025 Feb 16;13(5):97909. doi: 10.12998/wjcc.v13.i5.97909.
2
Advancing oral cancer care: Insights from Tongluo Jiedu prescription.
World J Clin Cases. 2024 Dec 16;12(35):6764-6769. doi: 10.12998/wjcc.v12.i35.6764.

本文引用的文献

1
Modern pharmacological research and application of medicinal insect .
Heliyon. 2024 Jan 13;10(2):e24613. doi: 10.1016/j.heliyon.2024.e24613. eCollection 2024 Jan 30.
2
Chinese herbal medicine compound of flavonoids adjunctive treatment for oral cancer.
J Formos Med Assoc. 2024 Aug;123(8):830-836. doi: 10.1016/j.jfma.2023.10.009. Epub 2023 Oct 31.
4
Molecular mechanism of ferulic acid and its derivatives in tumor progression.
Pharmacol Rep. 2023 Aug;75(4):891-906. doi: 10.1007/s43440-023-00494-0. Epub 2023 May 18.
6
Analysis of the active ingredients and health applications of cistanche.
Front Nutr. 2023 Mar 3;10:1101182. doi: 10.3389/fnut.2023.1101182. eCollection 2023.
7
Tumor Recurrence and Follow-Up Intervals in Oral Squamous Cell Carcinoma.
J Clin Med. 2022 Nov 29;11(23):7061. doi: 10.3390/jcm11237061.
8
Research progress on the antitumor effects of astragaloside IV.
Eur J Pharmacol. 2023 Jan 5;938:175449. doi: 10.1016/j.ejphar.2022.175449. Epub 2022 Dec 5.
9
Tumor microenvironment and immunotherapy of oral cancer.
Eur J Med Res. 2022 Oct 8;27(1):198. doi: 10.1186/s40001-022-00835-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验